| Name | Title | Contact Details |
|---|---|---|
Christopher Bond |
SVP Research and Early Development | Profile |
David Main |
President and Chief Executive Officer | Profile |
Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world`s largest biotechnology research hub.
We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.
jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.